Bioreactors Market by Mechanism (Airlift Bioreactors, Benchtop Bioreactors, Bubble Column Bioreactors), Usage (Full-scale Production, Lab-Scale Production, Pilot-scale Production), Control Type, Material, Scale, Usability, End User - Global Forecast 2024-
Description
Bioreactors Market by Mechanism (Airlift Bioreactors, Benchtop Bioreactors, Bubble Column Bioreactors), Usage (Full-scale Production, Lab-Scale Production, Pilot-scale Production), Control Type, Material, Scale, Usability, End User - Global Forecast 2024-2030
The Bioreactors Market size was estimated at USD 3.26 billion in 2023 and expected to reach USD 3.57 billion in 2024, at a CAGR 9.46% to reach USD 6.15 billion by 2030.
The bioreactor involves designing, producing, using, and maintaining specialized vessels that provide controlled environments for biological processes in various industries such as pharmaceuticals, food & beverage, biotechnology research facilities, and wastewater treatment plants. Increasing demand for personalized medicines and therapeutic antibodies, technological advancements in functional capabilities, and rising investments from government agencies and private sectors to expand the manufacturing of vaccines is driving the market growth. The rising usage of single-use bioreactors across pharmaceutical and waste treatment facilities is expanding the scope of the market. However, certain safety and maintenance issues with high usage of bioreactors are expected to hamper the market growth. Increasing research and development activities to introduce advanced bioreactors that enable biopharmaceutical businesses to improve the efficiency and precision of their operations is expected to create opportunities for market growth. The ongoing advancements in bioreactors are expected to develop standardized, repeatable cell-based products for regenerative medical applications and establish physiologically realistic in vitro models for drug testing.
Regional Insights
In the Americas region, specifically in North America, the demand for single-use or disposable bioreactors is increasing due to their ability to reduce cross-contamination risks. The highly developed life sciences industry and robust funding from both public and private sectors are creating a platform for the growth of the bioreactors market in the Americas. Increasing expansion of pharmaceutical manufacturing capabilities, and rapid industrialization are leading to greater production capacity requirements for vaccines, biosimilars, and stem cell therapies, subsequently, rising utilization of bioreactors in the Asia-Pacific. Moreover, government initiatives promoting R&D investments coupled with favorable regulatory policies are expected to benefit the market growth in the Asia-Pacific. In the EMEA, Europe occupies a dominant position within the global bioreactor market with nations such as Germany, France, and UK leading regional growth. This can be attributed to factors such as well-established pharmaceutical companies with robust product pipelines, supportive government policies, increasing collaborations between academic institutions and market players, and a strong emphasis on bioprocess innovation. On the other hand, the Middle East and Africa are gradually embracing bioreactors as countries such as Saudi Arabia and South Africa continue to invest in biopharma infrastructure development and capacity expansion.
Market Insights
- Market Dynamics
The market dynamics represent an ever-changing landscape of the Bioreactors Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.- Market Drivers
- Rapid growth of biopharmaceuticals and biologics industries
- Adoption of single-use bioreactors (subs) and hybrid bioreactors
- Market Restraints
- Maintenance issues and high power consumption issues with bioreactors
- Market Opportunities
- Continuous technological advancements in the development of novel bioreactors
- High potential of bioreactors in the wastewater treatment process
- Market Challenges
- Safety and environmental concerns associated with the use of bioreactors
- Market Segmentation Analysis
- Mechanism: Adoption of photo-bioreactors for the growth of photosynthetic microorganisms
- Usage: Preferences for full-scale production from various industries due to large volume processing capacity
- Control Type: Adoption of automated bioreactors due to high level of precision and consistency in process control
- Material : Increasing usage of stainless steel bioreactors in the pharmaceutical and biotech industries owing to their durability and scalability
- Scale: Suitability of 200L-1500L bioreactors for pilot-scale and small-scale commercial manufacturing processes
- Usability: Preferences for single-use bioreactors due to their flexibility, & reduced risk of cross-contamination
- End User: Increasing applicability in biopharmaceutical industry, for producing biotherapeutics including monoclonal antibodies & vaccines
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Bioreactors Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Bioreactors Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments- Sartorius Bioreactors Integrate Emerson Technology to Speed New Therapies to Market
Emerson has partnered strategically with the Sartorius life science group to seamlessly integrate the highly advanced Biostat STR Generation 3 family of bioreactors. This collaboration has resulted in the development of an integrated solution called the Biostat STR Generation 3 for Emerson's DeltaV. The collaboration between Emerson and Sartorius is a significant milestone in bioreactors, opening up new possibilities for advancing patient care and well-being. This partnership underscores the commitment of both companies to drive innovation and contribute to bioreactor technology.
Merger of Cytiva and Pall’s Life Sciences Business Now Complete
Cytiva, the life sciences business of Pall, has successfully merged into a single unified entity. With a global presence in 40 countries and a dedicated workforce of nearly 16,000 associates, Cytiva utilizes its extensive expertise spanning over 300 years to support customers in addressing significant biotechnology challenges. Cytiva's bioprocess business now encompasses Pall's former biotech portfolio, while its medical portfolio remains a distinct brand within Cytiva.
PBS Biotech and denovoMATRIX Join Forces to Boost Manufacturing Processes for Cell & Gene Therapies
PBS Biotech, the manufacturer of single-use bioreactors and provider of process development services, has announced a collaboration with denovoMATRIX, a supplier of next-generation biomimetic coating technologies. The primary objective of this partnership is to address the rising demand for safe and efficient manufacturing processes in the production of therapeutic cells. To achieve this goal, the collaborative team has utilized various matrices, including Biomimetic matrices, isoMATRIX, myMATRIX MSC, and beadMATRIX, in combination with PBS Vertical-Wheel bioreactors, for the cultivation of human bone marrow-derived mesenchymal stem/stromal cells (MSCs).
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Bioreactors Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Bioreactors Market, highlighting leading vendors and their innovative profiles. These include 3D Biotek LLC, ABEC, Inc., Adolf Kühner AG, BBI-biotech GmbH, Belach Bioteknik, Bioengineering AG, Bionet Servicios Técnicos, SL, Broadley-James Corporation, Cell Culture Company, LLC, Cellexus Limited, CerCell A/S, Cesco Bioengineering Co., Ltd., Danaher Corporation, Distek, Inc., Electrolab Biotech Limited, Eppendorf SE, FiberCell Systems Inc., G&G Technologies, Inc., GEA Group AG, Getinge AB, IKA-Werke GmbH & CO. KG, Infors AG, Lonza Group Ltd., Merck KGaA, PBS Biotech, Inc., Pierre Guérin SA, Praj Industries Limited, Sartorius AG, Shanghai LePure Biotech Co., Ltd., Solaris Biotechnolgy Srl by Donaldson Company, Inc., Solida Biotech GmBH, Terumo Corporation, Thermo Fisher Scientific Inc., WuXi Biologics (Cayman) Inc., and ZETA GmbH.
Market Segmentation & Coverage
This research report categorizes the Bioreactors Market to forecast the revenues and analyze trends in each of the following sub-markets:- Mechanism
- Airlift Bioreactors
- Benchtop Bioreactors
- Bubble Column Bioreactors
- Continuous Stirred Tank Bioreactors
- Fluidized Bed Bioreactors
- Microbial Bioreactors
- Multi-Parallel Bioreactors
- Packed Bed Bioreactors
- Photo-Bioreactors
- Usage
- Full-scale Production
- Lab-Scale Production
- Pilot-scale Production
- Control Type
- Automated
- Manual
- Material
- Glass
- Stainless Steel
- Scale
- 1500L-4000L
- 200L-1500L
- 20L-200L
- 5L-20L
- Above 4000L
- Usability
- Reusable
- Single-use
- End User
- Biopharmaceutical Companies & Manufacturers
- Contract Manufacturing Organizations & Contract Research Organizations
- Landfills & Waste Treatment Plants
- R&D Departments & Institutes
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
Please Note: PDF & Excel + Online Access - 1 Year
- Americas
- Market Drivers
Table of Contents
181 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rapid growth of biopharmaceuticals and biologics industries
- 5.1.1.2. Adoption of single-use bioreactors (subs) and hybrid bioreactors
- 5.1.2. Restraints
- 5.1.2.1. Maintenance issues and high power consumption issues with bioreactors
- 5.1.3. Opportunities
- 5.1.3.1. Continuous technological advancements in the development of novel bioreactors
- 5.1.3.2. High potential of bioreactors in the wastewater treatment process
- 5.1.4. Challenges
- 5.1.4.1. Safety and environmental concerns associated with the use of bioreactors
- 5.2. Market Segmentation Analysis
- 5.2.1. Mechanism: Adoption of photo-bioreactors for the growth of photosynthetic microorganisms
- 5.2.2. Usage: Preferences for full-scale production from various industries due to large volume processing capacity
- 5.2.3. Control Type: Adoption of automated bioreactors due to high level of precision and consistency in process control
- 5.2.4. Material : Increasing usage of stainless steel bioreactors in the pharmaceutical and biotech industries owing to their durability and scalability
- 5.2.5. Scale: Suitability of 200L-1500L bioreactors for pilot-scale and small-scale commercial manufacturing processes
- 5.2.6. Usability: Preferences for single-use bioreactors due to their flexibility, & reduced risk of cross-contamination
- 5.2.7. End User: Increasing applicability in biopharmaceutical industry, for producing biotherapeutics including monoclonal antibodies & vaccines
- 5.3. Market Trend Analysis
- 5.3.1. Emphasis on R&D activities for advanced bioreactors with the support of established production facilities in the Americas
- 5.3.2. Supportive government initiatives and enhanced technology adoption in drug manufacturing
- 5.3.3. Vigorous biopharmaceutical research activities and well-established players in the region
- 5.4. Cumulative Impact of Russia-Ukraine Conflict
- 5.5. Cumulative Impact of High Inflation
- 5.6. Porter’s Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
- 5.7. Value Chain & Critical Path Analysis
- 5.8. Regulatory Framework Analysis
- 6. Bioreactors Market, by Mechanism
- 6.1. Introduction
- 6.2. Airlift Bioreactors
- 6.3. Benchtop Bioreactors
- 6.4. Bubble Column Bioreactors
- 6.5. Continuous Stirred Tank Bioreactors
- 6.6. Fluidized Bed Bioreactors
- 6.7. Microbial Bioreactors
- 6.8. Multi-Parallel Bioreactors
- 6.9. Packed Bed Bioreactors
- 6.10. Photo-Bioreactors
- 7. Bioreactors Market, by Usage
- 7.1. Introduction
- 7.2. Full-scale Production
- 7.3. Lab-Scale Production
- 7.4. Pilot-scale Production
- 8. Bioreactors Market, by Control Type
- 8.1. Introduction
- 8.2. Automated
- 8.3. Manual
- 9. Bioreactors Market, by Material
- 9.1. Introduction
- 9.2. Glass
- 9.3. Stainless Steel
- 10. Bioreactors Market, by Scale
- 10.1. Introduction
- 10.2. 1500L-4000L
- 10.3. 200L-1500L
- 10.4. 20L-200L
- 10.5. 5L-20L
- 10.6. Above 4000L
- 11. Bioreactors Market, by Usability
- 11.1. Introduction
- 11.2. Reusable
- 11.3. Single-use
- 12. Bioreactors Market, by End User
- 12.1. Introduction
- 12.2. Biopharmaceutical Companies & Manufacturers
- 12.3. Contract Manufacturing Organizations & Contract Research Organizations
- 12.4. Landfills & Waste Treatment Plants
- 12.5. R&D Departments & Institutes
- 13. Americas Bioreactors Market
- 13.1. Introduction
- 13.2. Argentina
- 13.3. Brazil
- 13.4. Canada
- 13.5. Mexico
- 13.6. United States
- 14. Asia-Pacific Bioreactors Market
- 14.1. Introduction
- 14.2. Australia
- 14.3. China
- 14.4. India
- 14.5. Indonesia
- 14.6. Japan
- 14.7. Malaysia
- 14.8. Philippines
- 14.9. Singapore
- 14.10. South Korea
- 14.11. Taiwan
- 14.12. Thailand
- 14.13. Vietnam
- 15. Europe, Middle East & Africa Bioreactors Market
- 15.1. Introduction
- 15.2. Denmark
- 15.3. Egypt
- 15.4. Finland
- 15.5. France
- 15.6. Germany
- 15.7. Israel
- 15.8. Italy
- 15.9. Netherlands
- 15.10. Nigeria
- 15.11. Norway
- 15.12. Poland
- 15.13. Qatar
- 15.14. Russia
- 15.15. Saudi Arabia
- 15.16. South Africa
- 15.17. Spain
- 15.18. Sweden
- 15.19. Switzerland
- 15.20. Turkey
- 15.21. United Arab Emirates
- 15.22. United Kingdom
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2023
- 16.2. FPNV Positioning Matrix, 2023
- 16.3. Competitive Scenario Analysis
- 16.3.1. Sartorius Bioreactors Integrate Emerson Technology to Speed New Therapies to Market
- 16.3.2. Merger of Cytiva and Pall’s Life Sciences Business Now Complete
- 16.3.3. PBS Biotech and denovoMATRIX Join Forces to Boost Manufacturing Processes for Cell & Gene Therapies
- 16.3.4. Lonza and Adva Biotechnology Ltd. Agree to Expand Availability and Use of Automated Bioreactors with License to Lonza’s Patents
- 16.3.5. Novo Holdings co-leads Series C financing in LePure Biotech
- 16.3.6. PBS Biotech Raises USD 22 million to Expand Single-Use Manufacturing Products and Services for Cell Therapy Clients
- 16.3.7. Merck Gains Leading Perfusion Micro-Bioreactor with Erbi Biosystems Acquisition
- 16.3.8. Solaris Biotech and Wildtype Announce Agreement for Large-scale Bioreactors for Cultivated Seafood Production
- 16.3.9. STEMCELL Technologies and PBS Biotech Partner to Enable Robust Scale Up of Human Pluripotent Stem Cell 3D Cultures
- 16.3.10. Stämm Biotech Raises USD 17 Million To Develop Desktop 3D Printed Bioreactor
- 17. Competitive Portfolio
- 17.1. Key Company Profiles
- 17.2. Key Product Portfolio
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
